×

RNS Number : 5742D

Silverwood Brands PLC

03 April 2025

 

 3 April 2025

Silverwood Brands plc

("Silverwood", the "Company" or, together with its subsidiaries, the "Group") 

 

Leading Balmonds product now available in Boots stores and on Boots.com

 

Silverwood Brands plc (AQSE: SLWD) is pleased to announce that Balmonds' flagship product,  Skin Salvation, is now available in Boots stores and online at Boots.com.

 

Made with beeswax, organic oils and herbal tinctures, Skin Salvation is an award winning, 100% natural barrier balm, designed to prevent and treat the symptoms of eczema, psoriasis, and other dry skin conditions.

 

Alongside Skin Salvation, Balmonds produces a range of skin care solutions, including, creams, oils and salves, all based around natural and organic active ingredients. The Balmonds range is available directly from Balmonds.co.uk, as well as through channels including Amazon and Holland & Barrett. A wider range of Balmonds products will also be available soon on Boots.com. 

 

Andrew Gerrie, Executive Director at Silverwood, said, "Balmonds is one of Silverwood's core brands. Its hero product, Skin Salvation, is now available in over 300 Boots stores, and on Boots.com.

 

Roughly 10% of people in the UK are estimated to have eczema at some point in their lives and at least 50% consider themselves as having sensitive skin. The addition of Boots to our distribution channels should help significantly increase the reach of Balmonds and our share of the market for sensitive skin solutions."

 

For more information, please contact:

 

 

Silverwood Brands Plc Andrew Gerrie Paul Hodgins	info@silverwoodbrands.com
Peterhouse Capital Limited(Aquis Corporate Adviser) Mark Anwyl Narisha Ragoonanthun Brefo Gyasi	+44 (0)20 7469 0930

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXFXLFBEZLXBBB

Close

×

RNS Number : 4257D

4GLOBAL PLC

03 April 2025

 

 

 

3 April 2025

 

4GLOBAL plc

("4GLOBAL" or "the Company")

Sport England Contract Renewal and Expansion
 

4GLOBAL, a provider of data and technology for sports, fitness and wellness organisations to optimise operational and investment decisions, is pleased to announce that, following a competitive tender, it has secured a contract renewal and expansion with Sport England worth up to £4m over four years in equal terms.

 

Sport England initially procured 4GLOBAL in 2021 to provide performance data from public leisure facilities through its platform, Moving Communities, a decision-support tool that uses 4GLOBAL's dataset to aid understanding of where and how people engage in physical activity, enabling a more evidence-based approach to public investment. The platform has since played a central role in programmes such as the National Leisure Recovery Fund and the Swimming Pool Support Fund, tracking over 9 million active people across 1,000+ leisure facilities daily. 

 

This new Insight Solutions contract marks a significant expansion of the Sport England Moving Communities programme, underpinned by the Company's recently launched Insight.OS platform. 4GLOBAL's dataset now goes far beyond data public leisure facilities, incorporating a wide range of external sources such as wearable movement data and participation in community events, enabling broader and more detailed insights into physical activity patterns across the population with an unprecedented level of accuracy.

 

The expansion will support the delivery of Sport England's £250 million place-based investment strategy, enabling local and national bodies to use data-driven insights to target resources more effectively, overcome barriers to physical activity, monitor impact in real time, adjust delivery where needed and demonstrate to stakeholders that funding is being deployed effectively to maximise returns and drive meaningful outcomes.

 

Under the new agreement, 4GLOBAL will provide data and actionable insight to the wider ecosystem of sport and physical activity in England, engaging national governing bodies, local authorities, sports bodies and community programme providers to enable large scale, coordinated and effective delivery.

 

The increased breadth and depth of 4GLOBAL's dataset, now the largest repository of its kind in the UK, and its proven ability to generate actionable insights, were pivotal in securing the contract renewal and expansion.

 

Eloy Mazon, 4GLOBALCEO, said:"This new agreement is a strong endorsement of our ability to deepen and expand client relationships, which continues to lower our customer acquisition costs and drive EBITDA margin improvement. It also reflects the shift in our commercial model, with multi-year, multi-million-pound contracts underpinning our transition to Annual Recurring and Repeatable Revenue.

 

"The migration of clients to Insight Solutions is already delivering meaningful profitability gains, and the strength of our dataset not only enables us to offer richer insights to partners like Sport England but also reinforces a defensible competitive moat around our business. Wins like this contribute to a growing base of forward-looking revenue and position us well for long-term growth." 

 

Contacts
 

4GLOBAL	via Alma
Eloy Mazon (CEO)
Stuart Wooller (Group Finance Director)
Spark Advisory Partners (Nominated Adviser)	+44 (0)20 3368 3554
Neil Baldwin
Canaccord Genuity (Broker)	+44 (0)20 7523 8000
Bobbie Hilliam
Alma Strategic Communications	+44 (0)20 3405 0205
Rebecca Sanders-Hewett	4global@almastrategic.com
David Ison
Louisa El-Ahwal
Josh Royston
Will Ellis Hancock

 

About 4GLOBAL

 

4GLOBAL empowers sports, fitness and wellness organisations to make faster, smarter decisions about their operations, customers and investments through data and actionable insights.

 

It operates the largest sport participation and facility database in the world, with more than 4 billion data points.

 

Sourcing data from health & fitness operators, community programmes and other structured activities through its DataHub while drawing on information from GPS location updates and wearable devices, 4GLOBAL's unique combination of data assets provides a holistic view of physical activity patterns. 

 

4GLOBAL is at the forefront of predictive modelling and advanced analytics, with the insights it generates empowering customers to drive efficiencies, improve customer relationships and make more informed strategic decisions.

 

Its customers span both the public and private sectors, including central and local governments, cities, sporting bodies, trade associations, health & fitness operators and sports clubs.

 

Key markets include North America, the UK and Europe. Its headquarters are in London with offices in Miami and Istanbul.

 

4GLOBAL was founded in 2002 and listed on AIM in 2021 under the ticker 4GBL.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTQLLFBEZLZBBL

Close

×

RNS Number : 2449D

Genedrive PLC

02 April 2025

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive awarded additional grant funding under the DEVOTE programme

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces the extension of the highly successful multi-partner grant award from Innovate UK and the UK Government's Innovation Accelerator programme.

 

The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") grant, saw the Company benefit from approximately £1.2m through a combination of direct grant income, in-kind partner contributions, and other aligned funding.  The DEVOTE programme provided the Company with acute care patient access and supporting infrastructure to assess the real-world clinical performance of time-critical clinical tests in NHS settings.  The programme's lead partner, the University of Manchester ("UoM"), has supported the evaluation, validation, and implementation of the Genedrive® CYP2C19 ID Kit.

 

During the DEVOTE programme the Company completed validation and UKCA certification of the Genedrive® CYP2C19-ID Kit, which was subsequently published in the Journal of Molecular Diagnostics in December 2024 and recommended in final guidance from the UK's National Institute for Health and Care Excellence ("NICE") as the rapid genetics platform of choice for use in the NHS for Clopidogrel genotyping after Ischaemic or Transient Ischaemic Attack.

 

The significant success of the DEVOTE programme has led to follow-on Innovate UK Innovation Accelerator funding to further progress the DEVOTE project, of which the Company will receive £0.2m directly over the next six months for continuation of implementation of user-led product enhancements which are expected to further improve user experiences in rapid genetic testing environments.  

 

Gino Miele, Chief Executive Officer of genedrive plc, said: "The DEVOTE programme has been an incredible success and follow-on funding provides a further opportunity for us to partner once again with the University of Manchester in continuing development of time-critical genetic test solutions.  The additional non-dilutive grant funding facilitates the mitigation of development costs that would otherwise have been absorbed by the Company."

 

For further details please contact:

 

genedrive plc	+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser and Broker)	+44 (0)20 7418 8900
James Steel
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 orgenedrive@walbrookpr.com
Anna Dunphy	+44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com)

 

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS.  The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

 

About DEVOTE

 

The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme is a collaboration between academics, clinicians, and industry partners. It aims to accelerate the adoption of genomic technology into clinical practice by supporting companies through each aspect of the translational pathway.

Programme information is available at:

 

https://gmbusinessboard.com/news/innovation-accelerator-programme-extended-to-boost-growth-across-the-uk

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCIBMBTMTTMTBA

Close

×

RNS Number : 2449D

Genedrive PLC

02 April 2025

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive awarded additional grant funding under the DEVOTE programme

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces the extension of the highly successful multi-partner grant award from Innovate UK and the UK Government's Innovation Accelerator programme.

 

The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") grant, saw the Company benefit from approximately £1.2m through a combination of direct grant income, in-kind partner contributions, and other aligned funding.  The DEVOTE programme provided the Company with acute care patient access and supporting infrastructure to assess the real-world clinical performance of time-critical clinical tests in NHS settings.  The programme's lead partner, the University of Manchester ("UoM"), has supported the evaluation, validation, and implementation of the Genedrive® CYP2C19 ID Kit.

 

During the DEVOTE programme the Company completed validation and UKCA certification of the Genedrive® CYP2C19-ID Kit, which was subsequently published in the Journal of Molecular Diagnostics in December 2024 and recommended in final guidance from the UK's National Institute for Health and Care Excellence ("NICE") as the rapid genetics platform of choice for use in the NHS for Clopidogrel genotyping after Ischaemic or Transient Ischaemic Attack.

 

The significant success of the DEVOTE programme has led to follow-on Innovate UK Innovation Accelerator funding to further progress the DEVOTE project, of which the Company will receive £0.2m directly over the next six months for continuation of implementation of user-led product enhancements which are expected to further improve user experiences in rapid genetic testing environments.  

 

Gino Miele, Chief Executive Officer of genedrive plc, said: "The DEVOTE programme has been an incredible success and follow-on funding provides a further opportunity for us to partner once again with the University of Manchester in continuing development of time-critical genetic test solutions.  The additional non-dilutive grant funding facilitates the mitigation of development costs that would otherwise have been absorbed by the Company."

 

For further details please contact:

 

genedrive plc	+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser and Broker)	+44 (0)20 7418 8900
James Steel
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 orgenedrive@walbrookpr.com
Anna Dunphy	+44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com)

 

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS.  The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

 

About DEVOTE

 

The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme is a collaboration between academics, clinicians, and industry partners. It aims to accelerate the adoption of genomic technology into clinical practice by supporting companies through each aspect of the translational pathway.

Programme information is available at:

 

https://gmbusinessboard.com/news/innovation-accelerator-programme-extended-to-boost-growth-across-the-uk

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCIBMBTMTTMTBA

Close

×

RNS Number : 9938C

Northcoders Group PLC

01 April 2025

 

This is a Reach (i.e. non-regulatory) announcement, and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance

 

1April2025

 

Northcoders Group PLC

('Northcoders', the 'Group' or the 'Company')

 

New Consultancy contract wins

 

Northcoders to provide digital training to leading UK Building Society

and Manchester Airports Group

 

Northcoders (AIM:CODE), a market leader in technology training in the UK, is pleased to announce that its consultancy brand, Counter® has secured new contracts with Skipton Building Society ('Skipton'), one of the leading UK-based mutual financial services groups, and Manchester Airports Group ('MAG').

 

Following the successful integration of a Data Engineering team in 2024, Skipton has agreed terms for a second consultancy contract with Counter® in line with its strategy to grow internal capabilities and deliver its ambitious technology strategy. This team is supporting the delivery of the Society's brand-new customer web and mobile applications for its members using the Northcoders business model of deploying advanced engineers from Northcoders alumni and the Group's Tech Returners business. Beyond the immediate delivery to Skipton's members, a key benefit to the Society is the option for the Consultants to join Skipton for the next stage of their career.

 

Following an initial six-month engagement with MAG, a further three-month contract extension has been agreed. The embedded team of technologists will be working on a project to enhance MAG's three airport websites, and delivering an improved mobile experience.

 

Chris Hill, CEO of Northcoders, said:"We are delighted to announce the new contracts for our consultancy division, reflecting the recent progress made by Counter® in disrupting the traditional, hire, train, deploy market. With a focus specifically on the underserved technology training market, and offering the best-in-class Consultants, we are beginning to build a brand, relationships and pipeline to take material market share in the medium term, particularly with return customers like Manchester Airports Group.

 

"This demonstrates the successful diversification of Northcoders revenues as we mature as a business, addressing the UK's significant digital skills gap in private and public services and meeting technology transformation aspirations over the coming years."

 

June Powell, Engineering Enablement Lead, Skipton Building Society, said:"I had the pleasure of working with Counter® last year on a project, and I am delighted to have the opportunity to collaborate with them again in a different area of our business. I look forward to seeing more of their skills and experience in action as they continue to support The Society in our ongoing evolution. Their collaborative approach and the time they dedicate to truly understanding our culture make them an ideal fit for Skipton."

 

– Ends –

 

 

 

For further enquiries: Northcoders Group plc Via Burson Buchanan Chris Hill, CEO Tel: +44 (0) 20 7466 5000 Charlotte Prior, CFO investors.northcodersgroup.com               Burson Buchanan Tel: +44 (0) 20 7466 5000   Henry Harrison-Topham northcoders@buchanan.uk.com   Steph Whitmore Jesse McNab www.bursonbuchanan.com

 

 

Notes to Editors

 

Northcoders is a market leading provider of technology training for businesses and individuals with courses in, Software Engineering, Data Engineering, AI and Machine Learning, and Platform Engineering.  Founded in 2015, the Group provides the highest quality online training to students across the UK via its proven NCore technology platform.

 

Powered by IP rich technology, Northcoders offers boot camp courses to individuals from a range of backgrounds, delivered through virtual and physical learning.  The Group also works with blue chip corporates across multiple sectors to help them to achieve their digital requirements, with teams as a service and to supply innovative solutions for the upskilling and reskilling of employees. With a keen focus of inclusivity, diversity and quality at its core, Northcoders aims to address the digital skills gap in the UK to meet the increasing demand for digital specialists at all levels, from businesses and public agencies. 

 

Northcoders was admitted to trading on AIM in July 2021 with the ticker CODE.L.  For additional information please visitinvestors.northcodersgroup.com.

 

About Counter®

Counter®specialises in deploying UK-based teams of technologists into corporate clients, building dedicated teams that align technically and culturally with clients' long-term goals. Counter®is a challenger brand to the current tech consultancy, Offshore and Hire, Train and Deploy sector by offering a different approach underpinned by an efficient and scalable business model based on 100% utilisation rates for its Counter®consultants.

 

Counter®'s Consultants have either completed Northcoders' training and are proficient in modern cloud and software solutions, including AI/ML development, data and cloud engineering or are part of the Tech Returners network. The consultancy's robust model ensures that at the end of each engagement, clients have the option to onboard the consultants as full-time employees ('FTEs'), at no additional cost, reinforcing skill retention and continuity.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRABUGDXCSXDGUB

Close

×

RNS Number : 9559C

Croma Security Solutions Group PLC

01 April 2025

 

 

01 April 2025

Croma Security Solutions Group Plc

("CSSG", "Croma", "the "Company" or the "Group")

Acquisition of Peterborough Locksmith

Croma Security Solutions Group plc (AIM:CSSG) is pleased to announce that it has completed the acquisition of Benn Lock and Safe Limited ("Benn Lock & Safe"), a well-established, Peterborough based locksmith and security provider for a total  consideration of £200,000, to be satisfied as to £166,667 in cash and the balance through the issue of 38,535 ordinary shares which will be issued from Treasury at an issue price of 86.50 pence per share ("Consideration Shares"), representing average of the closing middle quotations over the five dealing days ending on the dealing day immediately before the completion Date.

Benn Lock & Safe was founded nearly 50 years ago, originally operating as a pure locksmith service before expanding into fire and electronic security solutions. The business has developed specialist expertise in servicing schools and multi-occupancy properties and is trusted by local vendors, police forces, and government sectors across Cambridgeshire. Benn Lock & Safe has developed its reputation through both a physical storefront in Peterborough and a successful online presence.

Croma already has a locksmith store in Peterborough, operating less than two miles from Benn Lock & Safe. The acquisition will enable Benn Lock & Safe to be combined with Croma's Peterborough branch, consolidating the two businesses into a single security centre. This will naturally create immediate cost savings and synergies but equally importantly, it will become the sole centre for security and locksmith services in the Peterborough area. The lease on the Benn Lock & Safe retail property allows for a 12-month break clause.

For the 12 months to 31 March 2024 Benn Lock & Safe generated revenues of £675,000 and profit before tax of £40,000. As at 28 February 2025, the net asset value of the assets being acquired was £90,000.

Phil Hunt, Managing Director of Benn Lock & Safe, said: "We have always prided ourselves on delivering expert locksmith and security services to our customers, and I am looking forward to continuing to do so as part of Croma. The Group's well-established model will provide us with the operational support and resources to enhance our offering while maintaining the trusted service that Benn Lock & Safe is known for."

Roberto Fiorentino, Chief Executive Officer, commented:"We are very pleased to welcome Benn Lock & Safe into the Group. This is a strategic acquisition for us, and also one that further evidences our acquisition model gaining traction, with independent locksmiths recognising the benefits of being part of our network. Benn Lock & Safe has seen first-hand how another locksmith in the area has successfully integrated into our proven model, which gave them confidence in making this transition. We believe this trend will continue, as we progress our pipeline of acquisition opportunities."

Total Voting Rights

Following the issue of the Consideration Shares from Treasury, the Company will continue to have 15,898,656 Ordinary Shares in issue, but with 2,130,401 held in treasury. Accordingly, the total number of voting rights in the Company will be 13,768,255 and shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information visit www.cssgroupplc.com or contact:

 

Croma Security Solutions Group Plc                                                       Tel: +44 44 (0)1489 566 166

Roberto Fiorentino, CEO

Teo Andreeva, CFO

 

Zeus                                                                                                            Tel: +44 (0)207 220 1666

(Nominated Adviser and Broker)

Mike Coe

James Bavister

 

Novella                                                                                                       Tel: +44 (0)203 151 7008

Tim Robertson

Chris Marsh

Safia Colebrook

 

Notes to editors:

 

Croma Security Solutions is an expanding technology led security solutions provider with over 50 years of specialist experience, delivering high-quality security solutions across locksmith, fire and security services for both domestic and commercial environments. The Groups network currently stands at 17 security centres, stretching from its headquarters in Southampton, across the Midlands and up to the Northwest. Croma services a range of sectors including health, education, leisure and entertainment, and utilities, and is trusted by national brands, including multiple NHS Trusts, with their complex security needs.

 

Croma's growth strategy is focused on establishing a national security network. In 2023, it sold its man-guarding business Vigilant for £6.5m, which has provided the capital to fund the expansion of the business. Croma is a proven acquirer of local, traditional locksmith businesses, which are developed into its network of modern security centres, offering both total security solutions and locksmith services to retail and commercial customers. The new security centres benefit from extended product ranges, centralised group services, and both a local and national customer base. Since the sale in 2023, Croma has added new businesses to its network, and has a strong pipeline of further locksmiths stores to be acquired into the network.

 

Croma is listed on the AIM market of the London Stock Exchange. Founded in 1970, it is headquartered in Southampton and has over 90 employees.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

ACQJBMBTMTJJBLA

Close

×

RNS Number : 5971X

Tracsis PLC

19 February 2025

 

19 February 2025

 

Tracsis plc

("Tracsis" or "the Group")

 

Contract signed for pay-as-you-go Tap Converter system

 

Tracsis (LSE: TRCS), a leading transport technology provider, is pleased to announce that, further to the announcement of Preferred Bidder status on 26 November 2024,  it has signed a multi-year contract withRail Settlement Plan, a division of Rail Delivery Group (RDG), to implement the core Tap Converter system that will powerpay-as-you-go (PAYG) travel in urban areas across National Rail, processing all related transactions and fare calculations.

 

Highlights

 

·     Major contract win, through a competitive bid process, to provide the central smart ticketing technology platform enabling PAYG travel in urban areas across National Rail.

·     The nationwide rollout of PAYG is central to the UK Government's stated vision for modernising rail travel with ticketing simplification and innovation high on its agenda.

·     Six Train Operating Companies (TOCs) on theNational Rail network currently use Tracsis' smart ticketing technology. This contract provides a long-term revenue opportunity as TOC and consumer adoption grows.

·     All Tracsis development activities are fully funded. Once deployed, the contract delivers a guaranteed minimum annual operating fee with additional transaction revenues based on the volume of PAYG transactions processed.

·     Development starts immediately with deployment and transactional revenue generation expected to begin in 2026.

 

Background

 

The Tap Converter system will be a centralised smart ticketing technology platform that processes 'tap' data from various sources such as smartcards, contactless bankcards and mobile apps/barcodes when passengers tap in and out at stations. It will also integrate with multiple modes of transport, supporting the delivery of London style PAYG ticketing for rail, bus and tram travel.

 

Tracsis will utilise its existing technology to construct journeys from these taps calculating the best fare while automatically applying entitlements, concessions, discounts and fare caps. Once calculated, the system provides this fare information to the TOC to charge the passenger and submits settlement records to the rail industry's settlement engine.

 

Tracsis is currently the only provider of an accredited PAYG ticketing platform on the National Rail network outside London, and this contract significantly extends the potential reachof Tracsis' technology. With the government and industry-wide push towards smarter, more flexible digital ticketing, PAYG adoption is expected to expand across the network, though the pace will vary by operator and region.

 

Timeline, Opportunity and Revenue Model

 

Tracsis has begun a period of funded development with deployment expected to begin in 2026. The six TOCs currently offering a PAYG solution using Tracsis' technology will continue to do so during this period.

 

Once the Tap Converter system is operational, Tracsis revenues will be based on the volume of transactions processed and this willbe driven by future customer adoption rates and system usage.

 

A total of 1.7 billion rail passenger journeys were recorded across Great Britain in the 12 months to September 20241.Tracsis estimates that PAYG transaction volumes using the Tap Converter system could in the medium term equate to 10-15% of total annual passenger journeys with commuters expected to drive the highest adoption rates.    

 

In 2024, Tracsis processed 2.25 million PAYG journeys. With the recent go-live of new PAYG deployments in Wales (contactless EMV) and Scotland (Tap&Pay) we expect to see accelerated growth in passenger journeys over the coming months ahead of the deployment of the Tap Converter system.

 

Transaction revenues from the Tap Converter system will start to accrue following deployment which is forecast to start in 2026. There is no change to the Board's expectation for the year ending 31 July 2025 following this contract win and Tracsis will issue its trading update on H1 performance on 26 February 2025.

 

Chris Barnes, Chief Executive Officer of Tracsis, commented:

 

"Weare delighted to be working with the Rail Delivery Group and Great British Railways Transition Team (GBRTT) to deliver this important pay-as-you-go ticketing solution on a nationwide basis. The contract represents a major milestone in our smart ticketing technology journey, with the potential to grow into a valuable, long-term partnership over time.

 

Digital transformation remains integral to the rail industry's future. The Government has made a commitment to expand pay-as-you-go ticketing across urban areas on the National Rail network and the Tap Converter system will position Tracsis as an important technology provider at the heart of this transformation."

Stewart Fox-Mills, Fares, Ticketing and Retail Programme Director at GBRTT and RDG, commented:

"We are working with industry partners to simplify the railway fares and ticketing system, making travel more convenient and flexible for all passengers. We are committed to developing a simpler fare system that enhances the overall customer experience and supports the long-term growth of rail travel.

The delivery of pay-as-you-go ticketing in urban areas is a high priority and we look forward to working with Tracsis on delivering the Tap Converter system that will provide the technical foundation for pay-as-you-go ticketing in urban areas."

 

1Source: Office of Rail and Road passenger rail usage data (published 19 December 2024)Passenger rail usage | ORR Data Portal

 

Enquiries:

Tracsis plc Chris Barnes, CEO Andy Kelly, CFO	+44 (0)845 125 9162
Berenberg (Nominated Adviser, Corporate Broker & Financial Adviser) Mark Whitmore / Richard Andrews / Mollie D'Arcy Rice James Thompson (QE)	+44 (0)20 3207 7800
Alma Strategic Communications David Ison / Rebecca Sanders-Hewett / Joe Pederzolli	+44 (0)20 3405 0205 tracsis@almastrategic.com

 

Notes to editors: 

 

·     Tracsis plc is a technology company and a leading provider of software and hardware products, data capture and data analytics/GIS services for the rail, traffic data and wider transport industries.

 

·     Tracsis's products and services are widely used to increase efficiency, reduce cost and risk, improve operational and asset performance, improve safety management and decision making capabilities and improve the overall end-user experience for clients and customers. 

 

·     The Group is split into two principal operating areas built around detailed industry knowledge and expertise:

 

–      Rail Technology & Services: A software, technology and product led business. It develops and supplies software that solves complex resource, asset optimisation and control problems for Train Operators, and smart ticketing, delay repay and other retail software to improve the customer experience for rail users. It also develops remote condition monitoring hardware, data acquisition software, and safety and risk management software for rail infrastructure providers.

–  Data, Analytics, Consultancy & Events: A largely services led business that focuses on data capture, data analytics, GIS, earth observation, data insights, consultancy and event traffic management within a range of transport and pedestrian rich environments. The business provides technology and bespoke products and data that underpin large scale intelligent transport systems, smart city planning and positive environmental decision making.

 

·     Tracsis has a blue-chip client base which includes all major UK transport owning groups, Network Rail, Passenger and Freight Train Operating Companies, the Department for Transport, TfL, multiple local authorities, major outdoor music and sporting event organisers, and a wide variety of large engineering and infrastructure companies. In North America our clients include Class 1 rail freight companies, transit operators, shortline railroads and several large rail served ports and industrials.

 

·     The business drives growth both organically and through acquisition and has made seventeen acquisitions since 2008.

 

For more information on Tracsis please visit http://www.tracsis.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTUWURRVVUUAUR

Close

×

RNS Number : 5703W

Newbury Racecourse PLC

11 February 2025

 

 

RNS Reach – non-regulatory announcement

 

11 February 2025

NEWBURY RACECOURSE PLC

(the "Company")

 

2025 Party in The Paddock

 

The Company today announces the final act to complete its 2025 Party in the Paddock line-up. In the past, the Company has hosted established acts such as Tom Jones, Meat Loaf, Olly Murs and Simply Red who have performed after racing at two key summer Saturday fixtures.

 

For 2025 the Company will be expanding these events and hosting a total of four events, the first of which is a double-headline combination of Sophie Ellis-Bextor and Ella Henderson on Saturday 19th July. Following this, Bjorn Again will perform on Friday 15th August and Clean Bandit on Saturday 16th August. James Bay will complete this year's line-up with a performance after racing on Saturday 20th September.     

 

Tickets are available to purchase fromwww.newburyracecourse.co.ukwith discounts offered for early and multi-day commitment.

 

Shaun Hinds, Chief Executive of Newbury Racecourse, commented: "We are delighted to announce an expanded Party in the Paddock line-up for 2025. By hosting this strong line up of established and popular artists we are hopeful that we have catered for a broad variety of music tastes and look forward to a fantastic summer of music and racing at Newbury".

 

 

 

For further information please contact:

 

Newbury Racecourse plc                                                                             Tel: 01635 40015

Shaun Hinds, Chief Executive

Mark Leigh, Finance Director

 

Allenby Capital Limited (AQSE Corporate adviser)                                  Tel: 0203 328 5656

Nick Naylor / Liz Kirchner (Corporate Finance)                   

 

Hudson Sandler                                                                                              Tel: 0207 796 4133

Charlie Jack

 

About Reach announcements

This is a RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.  Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRASFAFISEISEFE

Close

×

RNS Number : 5923W

Smarttech247 Group PLC

11 February 2025

 

Reach Announcement

11 February 2025

Smarttech247 Group PLC

 

("Smarttech247", the "Group" or the "Company")

 

Smarttech247 Secures Three-Year Contract Worth USD 925,000

 

Smarttech247 (AIM: S247), a multi-award-winning provider of AI-enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients, is pleased to announce it has signed a new additional contract with an existing automotive client worth USD 925,000 over three years.

 

This new additional contract will see an Endpoint Detection & Response (EDR) solution integrated into the existing Managed Detection and Response (MDR) service already supplied to Smarttech247's automotive client. This new EDR solution is designed to detect, investigate and respond to threats on endpoint devices such as computers, laptops, and servers, enhancing the client's existing cybersecurity resilience.

 

This new contract also reflects the execution of the Company's strategy to expand its annual recurring revenue by focusing on long-term, multi-year contracts and increasing the total contract value of existing agreements.

 

Raluca Saceanu, CEO of Smarttech247, commented:

 

"We are thrilled to be expanding our provision of services with another existing client, reinforcing our strong, ongoing relationship and highlighting the continued trust our clients have in our MDR expertise to protect their critical infrastructure.

 

"As organisations worldwide increasingly prioritise advanced threat detection and response, this latest contract showcases our ability to deliver security solutions at scale as our momentum continues to build."

 

-Ends –

 

*Smarttech247 is a recognised vendor in 2024 Gartner® Market Guide for Managed Detection and Response. 

 

For further information please contact:

 

Smarttech247 Group PLC	Tel: +353 21 206 6033
Ronan Murphy, Executive Chairman   Raluca Saceanu, Chief Executive Officer   Nicholas Lee, Finance Director
SPARK Advisory Partners Limited – Nominated Adviser	Tel: + 44 (0) 20 3368 3550
Mark Brady / Angus Campbell
Cavendish Capital Markets Limited – Corporate Broker	Tel: +44 (0) 20 7220 0500
Marc Milmo / Hamish Waller Tim Redfern / Sunila de Silva – Broking
Yellow Jersey PR	Tel: +44 (0) 20 3004 9512
Charles Goodwin / Annabelle Wills / Bessie Elliot

 

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only/non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

About Smarttech247

 

Smarttech247 is a multi-award winning automated MDR (Managed Detection & Response) company. Its platform is trusted by international organisations and provides threat intelligence with managed detection and response to provide actionable insights, 24/7 threat detection, investigation and response.

 

The Group's services are geared towards proactive prevention, and it achieves this by utilising the latest technologies, along with an experienced incident response team.

 

Smarttech247's offices are located in Ireland, United Kingdom, Romania, Poland and the USA. The Company was admitted to trading on the London Stock Exchange on 15 December 2022.

 

For further information please visitwww.smarttech247.com

 

*Gartner disclaimers

 

Market Guide for Managed Detection and Response, 24 June 2024, Pete Shoard, Andrew Davies, Mitchell Schneider, Angel Berrios, Craig Lawson.

 

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

 

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the

U.S. and internationally and is used herein with permission. All rights reserved.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAGPUAGPUPAGBU

Close

×

RNS Number : 9223V

Oxford BioDynamics PLC

05 February 2025

 

 

Oxford BioDynamics plc

("Oxford BioDynamics" or the "Company")

Oxford BioDynamics' EpiSwitch® CRC Blood Test Accurately
Detects both Cancer and Polyps

 

·   Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy of Oxford BioDynamics' EpiSwitch® blood-based Colorectal No-Stool Test (NST)

·   High accuracy of detection reported at 81% for early cancer stages and 82% for non-cancerous polyps

·   Discussions are underway with potential partners to bring this potentially evolutionary test to clinical practice

 

Oxford, UK – 5 February 2025– Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD's technology in a multi-centre study using blood to detect colorectal cancer (CRC), including early stage, and non-cancerous polyps with high accuracy1. 

 

The peer-reviewed work, published in the high-impact journal 'Cancers', was a collaboration between OBD, Norwich Medical School (University of East Anglia), University Hospitals NHS Trust, Hospital Sultana Bahiyah, Island Hospital Penang, Hospital Pulau Pinang, Hospital Sultanah Aminah, and Mount Miriam Cancer Hospital (Malaysia) under the direction of leading UK and Malaysian colorectal cancer experts.

 

Usingbloodsamples collected from 325 patients, the whole genome DNA screening for 3D EpiSwitch biomarkers in blood has identified and validated two eight-marker signatures (EpiSwitch® NST) that allow diagnosis of CRC andprecancerous polyps, respectively. Independent validation cohort testing demonstrated an exceptionally highaccuracy of detection – 81% for early cancer stages and 82% for non-cancerous polyps.Linking the top diagnostic biomarkers to nearby genes, OBD used the EpiSwitch KnowledgeBase platform to map pathways that help understand the processes contributing to the pathology of polyp and CRC progression.

 

Principle clinical lead Prof. Dmitry Pchejetski, Ph.D., Professorial Research Fellow and Head of the Tumour Microenvironment and Chemotherapy group at Norwich Medical School,said:

"I am excited by these findings. This test has the potential ability to detect early cancers and precancerous polyps with greater accuracy."

 

Dr Alexandre Akoulitchev, OBD's Chief Scientific Officeradded:

"Reliable and non-invasive detection of early stages of colorectal cancer, as well as the polyps, has been the focus of strenuous efforts by a number of big biomarker companies deploying common biomarker modalities. To date the results in terms of sensitivity of detection for polyps and positive predictive value for cancer have been disappointing. Our own approach and these reported results demonstrate the consistent accuracy of EpiSwitch technology for the most challenging patient stratifications and will allow us to progress our ongoing commercial discussions with third parties."

 

The peer-reviewed manuscript, titled "A New Blood-Based Epigenetic Diagnostic Biomarker Test (EpiSwitch® NST) with High Sensitivity and Positive Predictive Value for Colorectal Cancer and Precancerous Polyps" is available online in Cancers1 (www.mdpi.com/2072-6694/17/3/521).

 

Colorectal cancer

Globally, CRC is the third most common cancer type, accounting for 10% of all cancer cases. There were 1.9 million new cases and 930,000 deaths from the disease in 2020. More than 80% of CRC arises from adenomatous polyps and outgrowths. Around 75-95% of CRC cases occur in people with little or no genetic risk. Screening modalities such as colonoscopy, faecal immunochemical tests (FIT), FIT-DNA and cell-free DNA from CRC tumours in blood are current primary screening tests for early detection and prevention. Unfortunately, the non-invasive methods lack sensitivity to polyps and early CRC.

 

OBD's EpiSwitch pipeline development has delivered a blood-based Colorectal No-Stool Test (NST) which shows significant potential as an accurate and rapid cancer screening diagnostic for early stages of cancer (sensitivity 84% and specificity 79%) and non-cancerous polyps (sensitivity 79% and specificity 83%). This accurate, rapid, minimally invasive, and cost-effective NST test was built using OBD's EpiSwitch® 3D genomics platform and methodology. For each patient, NST captures a personal, systemic fingerprint of specific regulatory network changes associated with early stages of colorectal cancer and/or non-cancerous polyps.

 

References
1"A New Blood-Based Epigenetic Diagnostic Biomarker Test (EpiSwitch® NST) with High Sensitivity and Positive Predictive Value for Colorectal Cancer and Precancerous Polyps"Ewan Hunter 1, Heba Alshaker 2, Cicely Weston 1, Mutaz Issa 1, Shekinah Bautista 1, Abel Gebregzabhar 1, Anya Virdi 1, Ann Dring 1, Ryan Powell 1, Jayne Green 1, Roshan Lal 3, Vamsi Velchuru 3, Kamal Aryal 3, Muhammad Radzi Bin Abu Hassan 4, Goh Tiong Meng 5, Janisha Suriakant Patel 6, Shameera Pharveen Mohamed Gani 6, Chun Ren Lim 6, Thomas Guiel 7, Alexandre Akoulitchev  and Dmitri PchejetskiCancers2025, 17, 521. (https://www.mdpi.com/2072-6694/17/3/521)

 

-Ends-

 

For more information:

 

Oxford BioDynamics PLC Iain Ross, Executive Chairman Paul Stockdale, CFO	+44 (0)1865 518910
Shore Capital – Nominated Adviser and Joint Broker Advisory: Stephane Auton / Lucy Bowden Broking: Fiona Conroy	+44 (0)20 7408 4090
OAK Securities –JointBroker Jerry Keen / Henry Clarke /Damion Carruel	+44 (0)203 973 3678
WG Partners – Joint Broker David Wilson / Claes Spång /Satheesh Nadarajah / Erland Sternby	+44 (0)20 3705 9330
Vigo Consulting  Media / Analyst enquiries for OBD Rozi Morris	+44 (0)20 7390 0230 obd@vigoconsulting.com

 

 

Notes for Editors

 

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

 

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

 

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

 

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

 

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

 

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com,  X (@OxBioDynamics) or LinkedIn.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRASSIEFLEISEDE

Close